$Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review$
Código QR

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review

Thyroid Hürthle cell carcinoma, known as thyroid eosinophilic carcinoma, is a rare pathological type of differentiated thyroid cancer (DTC), representing 3-4% of all thyroid cancers. However, given the high risk of invasion and metastasis, thyroid Hürthle cell carcinoma has a relatively poor prognos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haihua He, Tangpeng Xu, Ping Li, Guohua Jia, Xiangpan Li, Qibin Song
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	thyroid Hürthle cell carcinoma immunotherapy radiotherapy PD-1/L1 GM-CSF Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/89eef32deb794bd1b8c28deef59c8881
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89eef32deb794bd1b8c28deef59c8881
record_format	dspace
spelling	oai:doaj.org-article:89eef32deb794bd1b8c28deef59c88812021-11-30T14:24:41ZAnti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review2234-943X10.3389/fonc.2021.782646https://doaj.org/article/89eef32deb794bd1b8c28deef59c88812021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.782646/fullhttps://doaj.org/toc/2234-943XThyroid Hürthle cell carcinoma, known as thyroid eosinophilic carcinoma, is a rare pathological type of differentiated thyroid cancer (DTC), representing 3-4% of all thyroid cancers. However, given the high risk of invasion and metastasis, thyroid Hürthle cell carcinoma has a relatively poor prognosis. Traditional treatment methods have limited effects on patients with metastatic thyroid cancers. Developing a valuable therapy for advanced thyroid carcinomas is an unfilled need, and immunotherapy could represent another choice for these tumors. We herein reported the case of a patient with recurrent advanced thyroid Hürthle cell cancer and positive programmed death-ligand 1 (PD-L1) expression, who suffered tumor progression after re-surgery, radiotherapy, and targeted therapy. It is encouraging that PD-1 inhibitors in combination with GM-CSF and stereotactic body irradiation (SBRT) on metastatic disease have a significant anti-tumor effect.Haihua HeTangpeng XuPing LiGuohua JiaXiangpan LiQibin SongFrontiers Media S.A.articlethyroid Hürthle cell carcinomaimmunotherapyradiotherapyPD-1/L1GM-CSFNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	thyroid Hürthle cell carcinoma immunotherapy radiotherapy PD-1/L1 GM-CSF Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	thyroid Hürthle cell carcinoma immunotherapy radiotherapy PD-1/L1 GM-CSF Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Haihua He Tangpeng Xu Ping Li Guohua Jia Xiangpan Li Qibin Song Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
description	Thyroid Hürthle cell carcinoma, known as thyroid eosinophilic carcinoma, is a rare pathological type of differentiated thyroid cancer (DTC), representing 3-4% of all thyroid cancers. However, given the high risk of invasion and metastasis, thyroid Hürthle cell carcinoma has a relatively poor prognosis. Traditional treatment methods have limited effects on patients with metastatic thyroid cancers. Developing a valuable therapy for advanced thyroid carcinomas is an unfilled need, and immunotherapy could represent another choice for these tumors. We herein reported the case of a patient with recurrent advanced thyroid Hürthle cell cancer and positive programmed death-ligand 1 (PD-L1) expression, who suffered tumor progression after re-surgery, radiotherapy, and targeted therapy. It is encouraging that PD-1 inhibitors in combination with GM-CSF and stereotactic body irradiation (SBRT) on metastatic disease have a significant anti-tumor effect.
format	article
author	Haihua He Tangpeng Xu Ping Li Guohua Jia Xiangpan Li Qibin Song
author_facet	Haihua He Tangpeng Xu Ping Li Guohua Jia Xiangpan Li Qibin Song
author_sort	Haihua He
title	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
title_short	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
title_full	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
title_fullStr	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
title_full_unstemmed	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
title_sort	anti-pd-1 immunotherapy combined with stereotactic body radiation therapy and gm-csf as salvage therapy in a pd-l1-positive patient with refractory metastatic thyroid hürthle cell carcinoma: a case report and literature review
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/89eef32deb794bd1b8c28deef59c8881
work_keys_str_mv	AT haihuahe antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview AT tangpengxu antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview AT pingli antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview AT guohuajia antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview AT xiangpanli antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview AT qibinsong antipd1immunotherapycombinedwithstereotacticbodyradiationtherapyandgmcsfassalvagetherapyinapdl1positivepatientwithrefractorymetastaticthyroidhurthlecellcarcinomaacasereportandliteraturereview
_version_	1718406515944062976

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review

Ejemplares similares